The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device thrombosis in the Absorb BVS group. We investigated whether all BVS platforms created equal outcomes. At 3-year follow-up novolimus-eluting BVS (Desolve Elixir Medical Corp., Sunnyvale, CA) achieved better outcomes compared with Absorb BVS. The scaffold thrombosis rate is still high with Absorb BVS despite pre- and post- dilatation. No scaffold thrombosis was present with Desolve BVS.
展开▼
机译：在临床实践中使用最多的生殖血管支架（BVS）的证据来自吸收试验和注册管理机构。吸收BV与金属支架的比较导致吸收BVS组靶病变失败和器件血栓形成的速率提高。我们调查了所有BVS平台是否创造了平等的结果。在3年的后续随访Novolimus洗脱的BVS（Desolve Elixir Medical Corp.，Sunnyvale，CA）与吸收BVS相比，更好的结果。尽管预先和膨胀，但支架血栓形成率仍然高，吸收BVS吸收。没有脱胶BVS没有支架血栓形成。
展开▼
